ArticleWorld journal of gastroenterology2020

Real-world cost-effectiveness associated with infliximab maintenance therapy for moderate to severe Crohn's disease in China.

Ji-Hao Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.